Sitemap > Breaking Research > Cardiovascular Disorders
Displaying 1301 - 1350 of 4862 results
- Prohemorrhagic and bleeding time activities of recombinant tissue plasminogen activator, heparin, aspirin, and a glycoprotein IIb/IIIa antagonist.
- Vasodilator effects of the endothelin ET receptor selective antagonist BMS-193884 in healthy men.
- p38 mitogen activated protein kinase mediates both death signaling and functional depression in the heart.
- Neutrophils and macrophages promote angiogenesis in the early stage of endometriosis in a mouse model.
- Therapeutic effect of anti-TNF-alpha antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis.
- Ghrelin improves renal function in mice with ischemic acute renal failure.
- Aspirin at low-intermediate concentrations protects retinal vessels in experimental diabetic retinopathy through non-platelet-mediated effects.
- Diabetic microangiopathy in ischemic limb is a disease of disturbance of the platelet-derived growth factor-BB/protein kinase C axis but not of impaired expression of angiogenic factors.
- Hypoxia inducible factor-1 activation by prolyl 4-hydroxylase-2 gene silencing attenuates myocardial ischemia reperfusion injury.
- Cardiomyocyte cell cycle activation ameliorates fibrosis in the atrium.
- Effects of nitrous oxide on the rat heart in vivo: another inhalational anesthetic that preconditions the heart?
- Pharmacological efficacy of CPU 86017 on hypoxic pulmonary hypertension in rats: mediated by direct inhibition of calcium channels and antioxidant action, but indirect effects on the ET-1 pathway.
- Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension.
- Improvement of EDHF by chronic ACE inhibition declines rapidly after withdrawal in rats with myocardial infarction.
- Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes.
- Effect of paclitaxel and mesenchymal stem cells seeding on ex vivo vascular endothelial repair and smooth muscle cells growth.
- Pioglitazone mimics preconditioning in the isolated perfused rat heart: a role for the prosurvival kinases PI3K and P42/44MAPK.
- An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats.
- Pomegranate flower extract diminishes cardiac fibrosis in Zucker diabetic fatty rats: modulation of cardiac endothelin-1 and nuclear factor-kappaB pathways.
- The protein kinase C-beta inhibitor, ruboxistaurin, for the treatment of diabetic microvascular complications.
- Effects of fasudil, a Rho-kinase inhibitor, on myocardial preconditioning in anesthetized rats.
- Structure-guided synthesis of tamoxifen analogs with improved selectivity for the orphan ERRgamma.
- Recurrence of atrial fibrillation after internal cardioversion of persistent atrial fibrillation: prognostic importance of electrophysiologic parameters.
- Biphasic effect of HMG-CoA reductase inhibitor, pitavastatin, on vascular endothelial cells and angiogenesis.
- Impact of diabetes on 12-month outcomes following coronary artery bypass graft surgery: results from the ROSETTA-CABG Registry.
- Statin therapy in Canadian patients with hypercholesterolemia: the Canadian Lipid Study -- Observational (CALIPSO).
- Isolated pulmonary hypertension secondary to rheumatoid arthritis.
- Elevated release of sCD40L from platelets of diabetic patients by thrombin, glucose and advanced glycation end products.
- Preclinical studies of the novel vascular disrupting agent MN-029.
- Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients.
- Vascular and fibrinolytic effects of intra-arterial tumour necrosis factor-alpha in patients with coronary heart disease.
- Aprotinin decreases ischemic damage during coronary revascularization.
- The role of exogenous carbon monoxide in the recovery of post-ischemic cardiac function in buffer perfused isolated rat hearts.
- Insulin improves the endothelium-independent relaxation and the contractile response in aorta from hypertensive diabetic rats.
- Heme oxygenase-1 gene expression increases vascular relaxation and decreases inducible nitric oxide synthase in diabetic rats.
- Protection from cardiac injury by induction of heme oxygenase-1 and nitric oxide synthase in a focal ischaemia-reperfusion model.
- Assessment of anti-estrogenic activity of tamoxifen in transgenic mice expressing an enhanced green fluorescent protein gene regulated by estrogen response element.
- Androstenediol analogs as ER-beta-selective SERMs.
- Decreased survival in diabetic patients with heart failure due to systolic dysfunction.
- The ruthenium-based nitric oxide scavenger, AMD6221, augments cardiovascular responsiveness to noradrenaline in rats with streptozotocin-induced diabetes.
- Does diabetes mellitus abolish the beneficial effect of primary coronary angioplasty on long-term risk of reinfarction after acute ST-segment elevation myocardial infarction compared with fibrinolysis? (A DANAMI-2 substudy).
- Administration of intracoronary eptifibatide during ST-elevation myocardial infarction.
- Explanation for the survival benefit of primary angioplasty over thrombolytic therapy in patients with ST-elevation acute myocardial infarction.
- Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
- Effect of Losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy.
- Relation of inflammation to peripheral arterial disease in the national health and nutrition examination survey, 1999-2002.
- Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies.
- Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes.
- Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency.
- Prophylaxis of Thromboembolism in Critical Care (PROTECT) Trial: a pilot study.
< Previous 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 Next >